A study from Mount Sinai Hospital in New York, still awaiting a final review by the scientific community, concludes that the vast majority of mild cases of COVID-19 generate antibodies for a time, which would allow people who have passed through the disease to live a normal life without fear of contagion.
The study has been published in MedRxiv and about fifteen scientists from the prestigious New York hospital have participated in it, among them the director of the research, the Spanish pathologist Carlos Cordón-Cardó.
The research was carried out on 1,343 candidates who had passed or thought they had passed the disease. “People with confirmed or suspected SARS-CoV-2 infection were examined by PCR to detect the presence of the viral genome and by an enzyme-linked immunosorbent assay to detect the presence of antibodies against the SARS-CoV-2 spike,” the study explains.
The result was that all but three confirmed SARS-CoV-2 patients, 624 people, “seroconverted when infected with SARS-CoV-2, while only 37.4% of the suspected SARS-CoV-2 patients seroconverted.
Data from the first group, those confirmed with the virus, mean that 98% generated antibodies, although it is not yet known how long. In any case, “PCR positivity was detected up to 28 days after symptom resolution”.
The scientists at Mount Sinai Hospital have thus concluded that “the vast majority of patients confirmed with COVID19 seroconvert, potentially providing immunity to re-infection”.